

Gibson Dunn Advises KKR on Participation in Series A Financing Round of Expedition Therapeutics

Firm News | October 14, 2025

Gibson Dunn advised KKR in connection with its participation in the Series A financing round of Expedition Therapeutics, Inc., an early-stage biotechnology company in-licensing assets from Asia for global development.

Gibson Dunn regularly advises investors and life sciences companies on venture financings and strategic transactions in the biotechnology sector.

The Gibson Dunn corporate team included Isabel Berger, Mark Goldman, and Sarah Reder. Christian Riis-Madsen, Pedro G. Soto, Jonas L. Jousma, and Alex Delipallas-O'Donnell advised on regulatory matters.

Related People

[Isabel Berger](#)

[Mark Goldman](#)

[Sarah Reder](#)

[Christian Riis-Madsen](#)

[Pedro G. Soto](#)

[Jonas L. Jousma](#)

[Alex Delipallas-O'Donnell](#)

Related Capabilities

[Mergers and Acquisitions](#)

[Emerging Companies / Venture Capital](#)

[Capital Markets](#)

[Private Equity](#)

[Antitrust and Competition](#)

[Life Sciences](#)